FDA advisory committee recommends combination Cyramza + erlotinib to treat EGFR-positive NSCLC.- Eli Lilly
Related news and insights
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
Genmab A/S announced that the FDA has approved Janssen’s Rybrevant (amivantamab-vmjw), a fully human bispecific antibody, for the treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Detailed results from the Phase III AENEAS trial showed that treatment with aumolertinib from EQRx + Hansoh Pharma, resulted in a clinically significant improvement in progression-free survival (PFS) as compared to gefitinib (Iressa) in first-line treatment in patients with Stage IIIB or IV non-small cell lung cancer (NSCLC) in patients with the most common types of EGFR mutations. In addition, the encouraging safety findings of less frequent rash and diarrhea confirmed the previously reported findings in the second-line APOLLO study.